BioXcel Therapeutics (BTAI) Granted FDA Fast Track Designation for BXCL501 for Acute Treatment of Agitation - https://t.co/gM21sWkdr3 https://t.co/CW572zrnQg
— IDRO (@IDROOhio) December 27, 2018
from Twitter https://twitter.com/IDROOhio
December 27, 2018 at 12:01PM
No comments:
Post a Comment